RIGL Q4 2021 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$20M+10.6% YoY

Gross Profit

$20M97.6% margin

Operating Income

-$21M-104.9% margin

Net Income

-$23M-110.9% margin

EPS (Diluted)

$-1.30

QoQ Revenue Growth

-5.3%

Cash Flow

Operating Cash Flow

-$19M

Free Cash Flow

-$19M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$167M

Total Liabilities

$137M

Stockholders' Equity

$30M

Cash & Equivalents

$19M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$20M	$18M	+10.6%
Gross Profit	$20M	$18M	+9.9%
Operating Income	-$21M	-$19M	-13.8%
Net Income	-$23M	-$19M	-17.7%

Revenue Segments

Gross product sales

$22M56%

Product sales, net

$18M44%

Contract revenues from collaborations

$2M5%

Research and development services and others

$2M4%

Government contract

$1M3%

License revenues

$199,0000%

Discounts and allowances

-$5M-12%